Loading clinical trials...
Loading clinical trials...
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Conditions
Interventions
Namodenoson
Placebo
Locations
24
Bosnia and Herzegovina
941 Univ of Clinical Centre of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
942 Health Inst General Hospital, Dept of Internal Medicine
Prijedor, Bosnia and Herzegovina
934 Second Dept of Internal Disease, MHAT Sveta Karidad EAD
Plovdiv, Bulgaria
932 Office of Gastroenterology, Medical Center Sansi EOOD
Rousse, Bulgaria
931 Clinic of Gastroenterology, Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda EAD, Sofia
Sofia, Bulgaria
933 Clinic of Gastroenterology, University Multiprofile Hosptial for Active Treatment
Sofia, Bulgaria
Start Date
December 10, 2021
Primary Completion Date
April 15, 2025
Completion Date
October 15, 2025
Last Updated
July 31, 2024
NCT03587831
NCT04383951
NCT02581085
NCT03997422
NCT04505436
NCT05499949
Lead Sponsor
Can-Fite BioPharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions